Registration Dossier

Toxicological information

Basic toxicokinetics

Currently viewing:

Administrative data

basic toxicokinetics, other
Type of information:
other: Evaluation of available information, expert statement
Adequacy of study:
key study
Study period:
2 (reliable with restrictions)
Justification for type of information:
Evaluation of available information. No specific studies are required

Data source

Reference Type:
other company data
Report date:

Materials and methods

Results and discussion

Toxicokinetic / pharmacokinetic studies

Details on absorption:
A prerequisite for a relevant absorption is that the substance can be dissolved in either aque-ous (e.g., gastrointestinal fluid, blood plasma, sweat) or lipophilic (e.g., lipoproteins, lipid membranes, triglycerides) media or in both. C.I. Pigment Yellow 17 can be considered insol-uble because it has an extremely low solubility in water (2,6 µg/L) and n-octanol (6,8 µg/L). Therefore, it is unlikely that C.I. Pigment Yellow 17 becomes systemically bioavailable after oral, dermal or inhalation exposure.
Based on the sub-chronic oral toxicity study with C.I. Pigment Yellow 12 absorption of tox-icologically significant amounts via the gastrointestinal tract is considered unlikely, since C.I. Pigment Yellow 12 did not show any effects on inner organs and blood or urine. No metabo-lites were determined.
The skin sensitisation studies with C.I. Pigment Yellow 12 indicate no local dermal bioavail-ability. Systemic availability also seems to be negligible after dermal exposure since no sys-temic signs of intoxication were seen after occlusive administration of 500 mg C.I. Pigment Yellow 17 per kg body weight in rabbits in the acute dermal irritation study.
Dermal absorption is, therefore, considered unlikely.
In the unlikely event of exposure to aerosolized pigment in respirable form, the substance is considered to behave like an inert dust. Therefore, the deposited pigment particles will mostly be cleared from the lung via the mucocilliary transport. As the pigment will not dis-solve quickly in the lung surfactant, the only efficient way the pigment can enter the body is via phagocytosis of pigment particles by lung macrophages followed by migration of the macrophages into the interstitium and into the draining lymph nodes. However, the internal dose delivered via this mechanism can be considered negligible.
Details on distribution in tissues:
The repeated dose toxicity study with C.I. Pigment Yellow 12 did not indicate any relevant histopathological changes in any of the investigated organs. In the sub-chronic inhalation study local effects were seen in the lungs, which were interpreted as the normal “clean-up” of the lung after inert dust exposure.
This may indicate that the pigment either does not affect specific organs as targets, i.e., is non-toxic, or is not distributed within the body in significant amounts. As indicated above, the physico-chemical parameters of the pigment support the conclusion that the pigment is not absorbed into the body and thus does not become systemically available. There were also no other signs of deposition of the pigment in any organ not exposed directly (except portal of entry: skin, lung, gut) including excretory organs, like the kidney, indicating that even exposure to high doses of the pigment does not lead to bioaccumulation in special compart-ments of the body.
Based on the available information on absorption distribution of the test material in the body in significant amounts is unlikely and specific hotspots of distribution cannot be identified.
Thus, it is concluded, that C.I. Pigment Yellow 17 is not systemically available at relevant concentrations within the organism.
There were no signs of bioaccumulation of the test material. The only exception could be the lung as portal of entry after prolonged exposure to excessive concentrations of dust (lung overload). This view is supported by the physical-chemical properties (solubility in water and octanol).
Details on excretion:
Considering the physico-chemical properties and the molecular structure and size of the mol-ecules and the absence of any indication of absorption and/or metabolism it is assumed that excretion, if any, is likely to occur via faeces. This notion is confirmed by the discoloration of faeces observed in the oral studies as the only alteration.

Metabolite characterisation studies

Details on metabolites:
Since the solution of the substance in cellular fluid or cellular membranes is a prerequisite for its metabolism, it is unlikely that the insoluble pigment becomes accessible for metabo-lizing systems in relevant amounts.
Diarylide yellow pigments are not or only to a negligible extend cleaved, taking into ac-count the negative results obtained with C.I. Pigment Yellow 17 in investigations on kinetic behavior.
The results of the mutagenicity tests provide qualitative information on the metabolic fate of C.I. Pigment Yellow 17. In the mutagenicity tests, the pigment as well as its close struc-tural analogues PY12 and PY13 proved to be non-mutagenic in the absence as well as in the presence of an exogenous metabolizing system, indicating that the pigment, even direct-ly exposed to metabolizing enzymes, is not converted into toxic or genotoxic metabolites. This conclusion is also supported by the lack of any morphological and histopathological changes of organs involved in xenobiotic metabolism, such as the liver, in the subacute and sub-chronic toxicity studies with C.I. Pigment Yellow 12. Furthermore, the missing skin or eye irritating or skin sensitizing properties argue against any interaction with biological ma-terial.
Therefore, C.I. Pigment Yellow 17 is considered to just pass through the intestinal tract without significant metabolism.

Bioaccessibility (or Bioavailability)

Bioaccessibility (or Bioavailability) testing results:
Bioavailability not likely

Applicant's summary and conclusion

Based on all available data, C.I. Pigment Yellow 17 does not exhibit conspicuous toxicoki-netic behaviour in the sense of accumulative and/or delayed effects with regard to the indi-vidual parameters absorption, distribution, metabolism and excretion. The only exception could be the lung as portal of entry after prolonged exposure to excessive concentrations of dust (lung overload).
The results from studies with dermal exposure indicate that C.I. Pigment Yellow 17 has a no relevant dermal absorptive potential. C.I. Pigment Yellow 17 is most probably not absorbed from the gastrointestinal tract in significant amounts.
Indications of an intense metabolism or a bio-accumulative potential do not exist as no tox-icity occurred even after chronic exposure, which points to no bio-accumulation potential and complete excretion of all possibly systemically available C.I. Pigment Yellow 17 and/or me-tabolites.
Executive summary:

Based on the available data base on C.I. Pigment Yellow 17 relevant information exists to make a qualitative evaluation of the toxicokinetic profile of this compound. This is in line with animal welfare considerations because additional animal tests can be avoided by such an evaluation. The substance is available in nano-form. The available data have partly been generated with non-specified material, but the conclusions drawn are considered valid for the nano form as well, because the material is chemically identical, and the physical properties are widely overlapping.


The results of basic toxicity testing give no reason to anticipate unusual characteristics regarding the toxico-kinetics of C.I. Pigment Yellow 17.C.I. Pigment Yellow 17 is not absorbed from the gastro-intestinal tract in toxicologically significant amounts. The data indicate that there is no relevant dermal absorption. After inhalation unspecific reactions to unreactive dust can be expected. Indications of a bio-accumulative potential as well as metabolism towards genotoxic sub-structures do not exist. Excretion of traces of possibly systemically available C.I. Pigment Yellow 17 and/or metabolites via faeces is likely.